Argenx — Sponsor Intelligence | 33 EU Trials

Filter these 33 trials by condition, phase, country and more.

Open in Search →

33 Registered trials

13 Recruiting

20 Completed trials

26 Countries active

18 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 14 Phase II/III: 6 Phase II: 9 Phase I/II: 1 Phase I: 1 Phase I (Other): 2

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

20 of 20 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Myasthenia gravis 6 Endocrine ophthalmopathy 2 Multifocal motor neuropathy 2 Ocular myasthenia 1 Amyotrophic lateral sclerosis 1 Dermatomyositis 1 Delayed graft function 1 Congenital myasthenic syndrome 1 Idiopathic inflammatory myopathy 1

Top IMPs

EFGARTIGIMOD ALFA 22 EMPASIPRUBART 7 ADIMANEBART 1

All trials — page 2

33 total

A safety and efficacy study of ARGX-119 in adult patients with Amyotrophic Lateral Sclerosis (ALS) (reALiSe) Ended

2024-511318-19-00 Phase II 5 countries ADIMANEBART
A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended

2023-509198-22-00 Phase III 10 countries EFGARTIGIMOD ALFA
A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended

2023-509197-35-00 Phase III 10 countries EFGARTIGIMOD ALFA
Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS) Ended

2023-503915-14-00 Phase II 3 countries EFGARTIGIMOD ALFA
A study to test how kidney problems influence the blood concentrations of efgartigimod Ended

2023-503992-88-00 Phase I (Other) 1 country
A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended

2023-508645-40-00 Phase II/III 14 countries EFGARTIGIMOD ALFA
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult… Ended

2024-515832-59-00 Phase III 10 countries EFGARTIGIMOD ALFA
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasth… Ended

2024-510932-36-00 Phase III 7 countries EFGARTIGIMOD ALFA
A long-term study to assess the safety and efficacy of efgartigimod in adult patients with primary immune thrombocytopenia (an autoimmune di… Ended

2024-511504-17-00 Phase III 4 countries EFGARTIGIMOD ALFA

Showing 25–33 of 33 trials

← All sponsors A–Z